LB-MED-305

Patient Name	:	Ms. MYLA GONZALES ELIZARIO	**Sample UID No.**	:	G4089797F
Age / Gender	:	43 Y 5 M / Female	**Sample Collected On**	:	23-06-2025 07:24
Patient ID	:	QLD089604	**Registered On**	:	23-06-2025 17:24
Referred By	:	Dr. AISHA	**Reported on**	:	26-06-2025 14:38
Referral Client	:	CITICARE MEDICAL CENTER	**External Patient ID**	:	37988
Emirates ID / Passport No	:	784198183920705	**Print Version**	:	V.1

Department of BIOCHEMISTRY

Investigation	Results	Flag	Units	Biological Reference Interval	Method
GLUCOSE (FASTING)	107		mg/dL	74 - 109	Hexokinase

Sample: Fluoride Plasma

Comments :

CLINICAL IMPLICATIONS:

ADA criteria for definitive test for diabetes:

1) Fasting blood glucose > 126 mg/dl (> 6.99 mmol/l) on at least two occasions.

2) Symptoms of diabetes plus random blood glucose > 200 mg/dl (> 11.1 mmol/l)

3) OGTT with 2 hrs. post load (75 gm glucose load) > 200 mg/dl (> 11.1 mmol/l) 4)HbA1c > 6.5%

INTERFERING FACTORS:

1) Steroids, diuretics, pregnancy, surgical procedures, anesthesia, obesity, smoking may cause elevated glucose levels.

2) Hematocrit > 55%, intense exercise, drug intake may cause lowered glucose level.

3)Dawn Phenomenon-Increase in blood glucose typically between 4.00am and 8.00 am due to counter-regulatory hormones.

RECOMMENDATION: As mild borderline cases may present with normal fasting glucose levels, recommended repeat testing different day.

REFERENCE: 1) Manual of Laboratory and Diagnostics -Frances Fischbach Marshall B. Dunning III [9th Edition]

2) Tietz clinical guide to Laboratory tests(Fourth edition) ALAN H.B.WU

- END OF REPORT -

"QLabs compliance with ISO 15189:2022 standards"

Mojahid Babiker
Lab Technologist

DHA No :82488066-001

Dr. Vidhya Mohan
Specialist Clinical Pathologist
Clinical Pathologist
DHA No. 23553203-004

Dr. Dheepa Manoharan
Medical Director
Specialist Microbiologist
DHA No. 00231751-004

QLABS Clinical Laboratory Off No 304, Carrera Building, Karama +971 4 578 2223 info@qlabsonline.com

LB-MED-305

Patient Name	:	Ms. MYLA GONZALES ELIZARIO	**Sample UID No.**	:	4089797
Age / Gender	:	43 Y 5 M / Female	**Sample Collected On**	:	23-06-2025 07:24
Patient ID	:	QLD089604	**Registered On**	:	23-06-2025 17:24
Referred By	:	Dr. AISHA	**Reported on**	:	26-06-2025 14:38
Referral Client	:	CITICARE MEDICAL CENTER	**External Patient ID**	:	37988
Emirates ID / Passport No	:	784198183920705	**Print Version**	:	V.1

Department of BIOCHEMISTRY

Investigation	Results	Flag	Units	Biological Reference Interval	Method
* C-REACTIVE PROTEIN (CRP)	23.9	H	mg/L	< 5	Particle enhanced immunoturbidimetric assay

Sample: Serum

Comments :

CLINICAL IMPLICATIONS:

1. CRP is the most sensitive acute phase reactant that can increase dramatically (100-fold or more) after severe trauma, bacterial infection, inflammation, surgeryor neoplastic proliferation. CRP levels may predict future cardiovascular events and can be used as a screening tool.

2. The traditional test of CRP has added significance over the elevated ESR, which may be influenced by altered physiologic states. CRP tends to increase before rises in antibody titres and ESR level occurs. CRP levels also tend to decrease sooner than ESR levels.

3. The traditional test for CRP is elevated in rheumatic fever, RA, myocardial infarction, malignancy, bacterial and viral infections. The positive test indicates active inflammation but not its cause. In RA, the traditional test for CRP becomes negative with successful treatment and indicates that the inflammation has subsided.

4.High sensitive measurement of CRP (hs-CRP) are useful in assessing vascular inflammation and cardiovascular stratification. A single test for hs-CRP may not reflect an individual patient basal hs-CRP level, therefore follow up tests or serial measurements may be required in patients presenting with increased hs-CRP levels.

INTERFERING FACTORS: Haemolysed or lipemic sample may alter the results.

REFERENCE:

1) Manual of Laboratory and Diagnostics -Frances Fischbach Marshall B. Dunning III [9th Edition]

2) Tietz clinical guide to Laboratory tests(Fourth edition) ALAN H.B.WU

- END OF REPORT -

Note:

"The analytes with asterix (*) symbol are non-accredited parameters.".

"QLabs compliance with ISO 15189:2022 standards"

Mojahid Babiker
Lab Technologist

DHA No :82488066-001

Dr. Vidhya Mohan
Specialist Clinical Pathologist
Clinical Pathologist
DHA No. 23553203-004

Dr. Dheepa Manoharan
Medical Director
Specialist Microbiologist
DHA No. 00231751-004

Patient Name	: Ms. MYLA GONZALES ELIZARIO		**Sample UID No.**	:	4089797
Age / Gender	: 43 Y 5 M / Female		**Sample Collected On**	:	23-06-2025 07:24
Patient ID	: QLD089604		**Registered On**	:	23-06-2025 17:24
Referred By	: Dr. AISHA		**Reported on**	:	26-06-2025 14:38
Referral Client	: CITICARE MEDICAL CENTER		**External Patient ID**	:	37988
Emirates ID / Passport No	: 784198183920705		**Print Version**	:	V.1

Department of BIOCHEMISTRY

LIPID PROFILE TEST

Investigation	Results	Flag	Units	Biological Reference Interval	Method
CHOLESTEROL (TOTAL)	174		mg/dl	Desirable: < 200 Borderline High: 200-239 High: > 240	Enzymatic colorimteric assay
TRIGLYCERIDES	47		mg/dl	Normal Up to 150 Borderline-High 150-199 High 200-499 Very High > 500	Enzymatic colorimetric test
HDL CHOLESTEROL	44		mg/dl	High risk up to 40 Low risk > 60	Homogeneous Enzymatic Colorimetric
LDL CHOLESTEROL DIRECT	123		mg/dl	Optimal up to < 100 Near Optimal: 100-129 Borderline : 130-159 High: 160-189 Very High: > 190	Enzymatic, colorimetric method
VLDL CHOLESTEROL	9	L	mg/dl	10-35	Calculation
NON-HDL CHOLESTEROL	130		mg/dl	Desirable < 130 Borderline 130 – 159 High >159	Calculation
TOTAL CHOLESTEROL / HDL RATIO	4.0		--	< 4.5	Calculation
LDL / HDL RATIO	2.8		--	Low Risk < 3.0 Borderline 3.1-6.0 High Risk >6.0	Calculation

Interpretation Notes :

CLINICAL IMPLICATIONS:

1. Cholesterol testing evaluates the risk for atherosclerosis, myocardial occlusion, and coronary artery occlusion. Elevated cholesterol levels are a major component in the hereditary hyper lipoproteinemia. It is also used to monitor effectiveness of diet, medications, lifestyle, and stress management.
2.The cholesterol to HDL ratio provides more information than does either value alone. When a slightly increased cholesterol is due to high HDL, therapy is not indicated.
3. LDL cholesterol has a longer shelf life and determines the CHD risk.

INTERFERING FACTORS:

1. Seasonal and positional variations may alter cholesterol levels. Estrogens, ascorbic acid, bilirubin decrease the cholesterol levels .Pregnancy, bile salt, high saturated fat, and high cholesterol diet may increase the cholesterol values. Prolonged fasting with ketosis may increase the value.
2. Increased levels of HDL may be associated with estrogen therapy, drugs like steroids, alcohol and insulin therapy. Decreased levels are associated with stress, recent illness, starvation, obesity, smoking, hyper triglyceridemia, lack of exercise.
3. Increased LDL may be associated with pregnancy, drugs like steroids. Decreased LDL are found in women under estrogen therapy. No fasting may cause false elevation.
4. A transient increase in triglycerides occurs following heavy meal, alcohol ingestion, pregnancy, acute illness like cold ,flu, obesity, physical

- END OF REPORT -

"QLabs compliance with ISO 15189:2022 standards"

Mojahid Babiker
Lab Technologist

DHA No :82488066-001

Dr. Vidhya Mohan
Specialist Clinical Pathologist
Clinical Pathologist
DHA No. 23553203-004

Dr. Dheepa Manoharan
Medical Director
Specialist Microbiologist
DHA No. 00231751-004

Patient Name	:	Ms. MYLA GONZALES ELIZARIO	**Sample UID No.**	:	4089797
Age / Gender	:	43 Y 5 M / Female	**Sample Collected On**	:	23-06-2025 07:24
Patient ID	:	QLD089604	**Registered On**	:	23-06-2025 17:24
Referred By	:	Dr. AISHA	**Reported on**	:	26-06-2025 14:38
Referral Client	:	CITICARE MEDICAL CENTER	**External Patient ID**	:	37988
Emirates ID / Passport No	:	784198183920705	**Print Version**	:	V.1

Department of BIOCHEMISTRY

LIPID PROFILE TEST

Investigation	Results	Flag	Units	Biological Reference Interval	Method

inactivity ,smoking. Transient decrease occurs after strenuous exercise, weight loss.

RECOMMENDATION:

1. Cholesterol levels >200 mg/dl should be retested and the results averaged and if the results differ by > than 10%, a third test need to be done for confirmation. Perform a comprehensive lipoprotein analysis if cholesterol levels are not lowered within 6 months after start of therapy. If the values are altered in a normal condition, recommended to follow a stable diet for 1 week and overnight fasting (9 to 12 hours)before repeating the test.
2. Cholesterol and HDL should not be measured immediately after MI. A 3 month wait is suggested.
3. If triglyceride levels are more than 400mg/dl or >10.36mmol/L recommended to fast overnight(9 to 12 hours) and retest .Because of biological and analytical variation, at least 2 serial sample may be necessary for clinical decision making. VLDL cannot be calculated if triglycerides are more than 400mg/dl

REFERENCE: 1) Manual of Laboratory and Diagnostics -Frances Fischbach Marshall B. Dunning III [9th Edition]
2) Tietz clinical guide to Laboratory tests(Fourth edition) ALAN H.B.WU

Sample: Serum

- END OF REPORT -

"QLabs compliance with ISO 15189:2022 standards"

Mojahid Babiker
Lab Technologist

DHA No :82488066-001

Dr. Vidhya Mohan
Specialist Clinical Pathologist
Clinical Pathologist
DHA No. 23553203-004

Dr. Dheepa Manoharan
Medical Director
Specialist Microbiologist
DHA No. 00231751-004

LB-MED-305

Patient Name	: Ms. MYLA GONZALES ELIZARIO		**Sample UID No.**	:	EB4089797
Age / Gender	: 43 Y 5 M / Female		**Sample Collected On**	:	23-06-2025 07:24
Patient ID	: QLD089604		**Registered On**	:	23-06-2025 17:24
Referred By	: Dr. AISHA		**Reported on**	:	23-06-2025 22:36
Referral Client	: CITICARE MEDICAL CENTER		**External Patient ID**	:	37988
Emirates ID / Passport No	: 784198183920705		**Print Version**	:	V.1

Department of HEMATOLOGY

COMPREHENSIVE COMPLETE BLOOD COUNT

Investigation	Results	Flag	Units	Biological Reference Interval	Method
HEMOGLOBIN	12.4		g/dl	12-15	photometric
RBC COUNT	4.14		10^6/uL	3.8-4.8	Electrical Impedance
HEMATOCRIT	36.4	L	%	37-47	Calculation
MCV	87.8		fL	78-100	Calculation
MCH	30		pg	27-31	Calculation
MCHC	34.1		g/dl	31-35	Calculation
RDW	12.4		%	9.3-16	Calculation
RDW-SD	38.5	L	fL	38.9-49	Calculation
MPV	8.5	L	fL	8.8-12.5	Calculation
PLATELET COUNT	257		10^3/uL	150-400	Electrical Impedance
* PCT	0.2		%	0.01-9.99	Calculation
* PDW	16.2			0.1-99.9	Calculation
* NUCLEATED RBC (NRBC)^	0.23		/100 WBC		Flow Cytometry
* ABSOLUTE NRBC COUNT^	0.02		10^3/uL		Calculation
* EARLY GRANULOCYTE COUNT (EGC)^	0.23		%		Flow Cytometry
* ABSOLUTE EGC^	0.02		10^3/uL		Calculation
WBC COUNT	7.4		10^3/uL	4-11	Electrical Impedance
* Neutrophil	61.41		%	40-80	VCS-Method
* Lymphocyte	25.41		%	20-40	VCS-Method
* Eosinophil	3.87		%	1-8	VCS-Method
* Monocyte	8.41		%	2-10	VCS-Method
* Basophil	0.9		%	0-2	VCS-Method
* ABSOLUTE NEUTROPHIL COUNT	4.53		10^3/uL	1.5-7	Calculation
* ABSOLUTE LYMPHOCYTE COUNT	1.87		10^3/uL	1.5-4	Calculation
* ABSOLUTE MONOCYTE COUNT	0.62		10^3/uL	0-0.8	Calculation
* ABSOLUTE EOSINOPHIL COUNT	0.28		10^3/uL	0-0.6	Calculation
* ABSOLUTE BASOPHIL COUNT	0.07		10^3/uL	0-0.2	Calculation

Sample: EDTA Whole Blood

- END OF REPORT -

Note:

"The analytes with asterix (*) symbol are non-accredited parameters.".

"QLabs compliance with ISO 15189:2022 standards"

Ebin C Lorance
Lab Technologist

DHA No. 57146854-002

Dr. Vidhya Mohan
Specialist Clinical Pathologist
Clinical Pathologist
DHA No. 23553203-004

QLABS Clinical Laboratory Off No 304, Carrera Building, Karama +971 4 578 2223 info@qlabsonline.com

LB-MED-305

Patient Name	:	Ms. MYLA GONZALES ELIZARIO	**Sample UID No.**	:	4089797
Age / Gender	:	43 Y 5 M / Female	**Sample Collected On**	:	23-06-2025 07:24
Patient ID	:	QLD089604	**Registered On**	:	23-06-2025 17:24
Referred By	:	Dr. AISHA	**Reported on**	:	26-06-2025 14:38
Referral Client	:	CITICARE MEDICAL CENTER	**External Patient ID**	:	37988
Emirates ID / Passport No	:	784198183920705	**Print Version**	:	V.1

Department of IMMUNOLOGY

Investigation	Results	Flag	Units	Biological Reference Interval	Method
VITAMIN D, 25-OH (TOTAL)	27.6		ng/mL	Deficient : ≤ 20 insufficient: 21-29 Sufficient: ≥ 30 Toxicity : >80	ECLIA

Sample: Serum

Comments :

CLINICAL IMPLICATIONS:

1. Increased Vitamin D levels are seen in gastrointestinal symptoms like anorexia, nausea, vomiting, constipation, hypercalcemia, renal colic, supplements, normal growing children, pregnant and lactating females, tuberculosis, idiopathic hypercalciuria, sarcoidosis. Levels can increase to 200 -300pg/ml during treatment of osteoma Lacia with physiological doses of vitamin D.
2. Decreased levels are seen in Inadequate diet, Inadequate exposure to sunlight, liver disease, Malabsorption syndrome, osteoma Lacia, Anticonvulsants, rickets, chronic renal failure, pseudohypoparathyroidism, post-menopausal osteoporosis and adults with insulin requiring diabetes mellitus.
3. 25(OH) levels do not indicate clinical vitamin D status in patients with chronic renal failure or type 1 vitamin D dependent rickets or when calcitriol is used as a supplement.

INTERFERING FACTORS:

Age, season of the year, diarrhoea or vomiting, certain drugs, diseases, and long term hyperalimentation are the factors that may interfere with the vitamin levels.

RECOMMENDATION:

Recommended to evaluate alternate cause of impaired mineralization ,if the levels are not consistent with the suspected diagnosis.

REFERENCE:

1) Manual of Laboratory and Diagnostics -Frances Fischbach Marshall B. Dunning III [9th Edition]

2) Tietz clinical guide to Laboratory tests(Fourth edition) ALAN H.B.WU

3) Clinical microbiology procedures 4th edition AMY L LEBER

- END OF REPORT -

"QLabs compliance with ISO 15189:2022 standards"

Mojahid Babiker
Lab Technologist

DHA No :82488066-001

Dr. Vidhya Mohan
Specialist Clinical Pathologist
Clinical Pathologist
DHA No. 23553203-004

Dr. Dheepa Manoharan
Medical Director
Specialist Microbiologist
DHA No. 00231751-004

QLABS Clinical Laboratory Off No 304, Carrera Building, Karama +971 4 578 2223 info@qlabsonline.com